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Abstract
Background: The national Human Papillomavirus (HPV) Immunisation Programme in New Zealand was introduced
in 2008, and involves routine vaccination of girls 12–13 years with a catch-up for females aged up to 19 years. The
aims of this study were to measure the pre-vaccination prevalence of oncogenic HPV infection in women aged
20–69 years who were participating in the New Zealand National Cervical Screening Programme (NZ-NCSP) and
who were: (1) referred with high grade cytology with a subsequent histologically-confirmed high grade cervical
intraepithelial neoplasia (CIN2/3) or adenocarcinoma in situ (AIS); or (2) were in the wider group of women who
had a cytological prediction of high grade squamous disease or glandular abnormality (ASC-H/ HSIL+/AGC/AIS).
Methods: Women aged 20–69 years appearing on the NZ-NCSP register between August 2009-February 2011 with
a cytology record of ASC-H/HSIL+/AGC/AIS were invited to participate in the study. Liquid-based cytology
specimens were tested for 37 HPV types using Linear Array genotyping. The prevalence of type-specific HPV
infection was reported within women with histologically-confirmed CIN 2/3 and within the wider group with ASC-
H/HSIL+/AGC/AIS cytology. Age-specific trends for the relative proportion of HPV 16/18 vs. other oncogenic types
in CIN2/3 were assessed.
Results: A total of 594 women with ASC-H/HSIL+/AGC/AIS cytology and a valid HPV test were recruited; of these
356 (60%) had confirmed CIN2/3 and 6 (1%) had confirmed AIS or glandular dysplasia. Positivity rates for any
oncogenic HPV infection and for HPV16 and/or 18 within confirmed CIN2/3-AIS were 95% (95%CI: 92-97%) and 60%
(54-65%) respectively; in all women with ASC-H/HSIL+/AGC/AIS cytology it was 87% (84-89%) and 53% (49-57%),
respectively. The most common reported HPV types in women with CIN 2/3 were 16 (51%), 52 (19%), 31 (17%), 33
(13%) and 18 (12%). A trend for higher rates of HPV 16/18 infection compared to other oncogenic types was
observed in younger women (p=0.0006).
Conclusions: The prevalence of HPV 16/18 in confirmed high grade disease in New Zealand is comparable to that
observed in Australia and European countries. Test positivity rates for type 52 appear higher than in comparable
studies in other developed countries. A greater proportion of high grade lesions in younger women appear to be
associated with HPV 16/18 infection.
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Background
Infection with the oncogenic types of human papillo-
mavirus has been associated with a higher cumulative
risk over time of developing histologically-confirmed
high grade cervical precancerous disease (defined as
cervical intraepithelial neoplasia grade 2/3 [CIN2/3] or
adenocarcinoma in situ [AIS]) [1,2]. A recently updated
worldwide meta-analysis of oncogenic HPV prevalence in
CIN3 reported that the most common types were 16
(58.2%), followed by 31(11.1%), 52(10.2%), 33(9.1%) then
58(9.0%) [3]. However, there appear to be significant
regional variations - for example, in Asia the estimated
prevalence of HPV 16 in high grade disease has been
reported as 37.9%, whereas for the North America it is
56.8% [4].
Given the geographic proximity of Australia to New
Zealand, a previously used working assumption has been
that the two countries have similar HPV infection
patterns [5]. In practice, however, no national data on
HPV prevalence have been reported for New Zealand;
and potential differences may exist because the ethnic
composition in each of the countries are somewhat
dissimilar, such that in the 2011 Australian Census 2.5%
of respondents identified themselves as Aboriginal and/or
Torres Strait Islander, whereas in the 2006 New Zealand
Census 14.6% identified themselves as Maori [6,7]. In
Australia, estimates of the type-specific prevalence of
oncogenic HPV have been reported in cervical cancer, [8]
high grade disease, [9,10] and normal cytology; [11] but
none of these measures have been previously reported for
New Zealand.
For countries implementing HPV vaccination programs,
a baseline measure of oncogenic HPV infection in high
grade disease provides the capacity to estimate the potential
burden of precancerous disease which may be avertable via
vaccination. Ongoing surveillance will then provide an
opportunity to monitor vaccine effectiveness. In September
2008, New Zealand commenced implementation of a
national HPV immunization program using the Gardasil™
vaccine (Merck, Whitehouse Station, NJ, USA) [12]. The
vaccine has been shown to confer high levels of protection
against new infections with HPV types 6, 11, 16 and 18 in
women naïve for those types [13,14]. Vaccine delivery in
New Zealand is ongoing for female cohorts aged 12–13
years, and girls and young women born from 1 January
1990 (aged 18 years or younger at the start of the program)
are eligible to participate in a catch-up program up to
their 20th birthday. The vaccine was available through
participating schools or from family doctors, local health
centres and some Family Planning clinics [12].
The primary aims of the current study were to provide a
baseline measure of oncogenic HPV infection in women
aged 20–69 years among: (1) a potentially ‘enriched’ popu-
lation of women with high grade cervical lesions, defined
as a those referred with a high grade cytology report and
who had a histologically-confirmed high grade CIN lesion
or adenocarcinoma in situ; and (2) among all women with
a cytological prediction of high grade squamous disease
or glandular abnormality (ASC-H/HSIL+/AGC/AIS) who
were participating in the New Zealand National Cervical
Screening Programme (NZ-NCSP). The secondary aim of
the analysis was to compare oncogenic HPV prevalence in
women with high grade disease in New Zealand with prior
estimates from Australia and from other regions.
Methods
Study design and recruitment
We used a cross-sectional design for the study. Eligible
participants, defined as women aged 20–69 years with a
high grade cytology result notified to the New Zealand
National Cervical Screening Programme Register (NCSP-R)
between August 2009 and February 2011, were invited
to participate. Established in 1990, the NCSP-R is a
country-wide national register that is used to monitor New
Zealand’s cervical screening participation, compliance with
recommended management, laboratory and colposcopy
standards and cervical abnormality rates. The representa-
tiveness of the NCSP-R of the cervical screening population
is underpinned by legislation that requires all cervical speci-
mens in New Zealand to be sent to the NCSP-R [15]. The
register holds information on each woman including their
national unique health identifier, name, address, date of
birth, ethnicity, and cervical screening history. Women are
able to withdraw from the register if they choose, but only
a small proportion choose to do so - during the latter half
of 2009 only 0.003% of women withdrew [15]. Cytology in
New Zealand is classified according to the Bethesda 2001
New Zealand Modified Cytology Classification System
(2005) [16]. A high grade cytology report is defined as a
classification of high grade squamous intra-epithelial
lesion (HSIL), atypical squamous cytology where high grade
abnormalities cannot be excluded (ASC-H), abnormal glan-
dular lesions (AGC, AIS), or cytology suggestive of invasion
(squamous cell carcinoma [SC], adenocarcinoma involving
endocervix [AC1], endometrium [AC2], extrauterine [AC3],
adenocarcinoma alone [AC4]; malignant neoplasm [AC5]).
Women on the NSCP-R with a notified high grade
cytology result were invited to participate in the study. A
recruitment flowchart is provided in Figures A1 and A2
in the Additional file 1: Appendix. Contact with eligible
participants was made after they were informed by their
smear-taker of their high grade cytology result. Women
were excluded if they were pregnant, had a health condition
preventing participation in data collection, had a cervical
smear suspicious of cancer, or had had a total hysterectomy
(women with a total hysterectomy may have undergone
cervical screening previously. These cases of hysterectomy
are recorded on the NCSP-R). Eligible participants were
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contacted by telephone by a trained study recruitment
officer located at the NCSP. Eligible women who consented
to participate were asked to provide a cervical sample for
HPV testing during colposcopy or have residual cytological
material from their referral high grade smear tested for
HPV within 4 weeks of the date that the cytology sample
had been collected. Because a small proportion of partici-
pants were expected to have been in the target age group
for HPV vaccination, women were also asked to self-report
whether they had been vaccinated.
Follow-up with colposcopy with or without biopsy
proceeded accorded to standard clinical referral protocols.
For each woman, the most severe disease ranking in the
SNOMED diagnostic (morphology M) category observed
over the 6 month period following the high grade cytology
report was used to classify histology grade. Because the
current study included only women referred with a high
grade cytological result, the sub-group with confirmed high
grade disease can be considered an ‘enriched’ population
with respect to other studies of HPV in high grade CIN,
since the majority of other studies have enrolled women
referred with a smear showing any grade of abnormality.
Sample collection and processing
Depending on the usual practice at each collection site,
either SurePath™ (Becton Dickinson, Franklin Lakes, NJ,
USA) or ThinPrep™ (Hologic, Malborough, MA, USA)
liquid-based cytology (LBC) collection systems were
used. Both cytology collection systems have been validated
for use for HPV detection using Linear ArrayW HPV
Genotyping Test (Roche, Pleasanton, CA, USA) [17]. LBC
samples were processed according to previously described
methods [18]. Briefly, the process involved 1 mL of material
aliquoted and pelleted for centrifugation at 13,000 r.p.m.
Cell pellets were then re-suspended into 200μl of
sterile phosphate-buffered saline. DNA was subsequently
extracted using the automated MagNA Pure LC with
the DNA-I extraction kit on the high performance
protocol (Roche Diagnostics, Auckland, New Zealand).
Once extracted, DNA material was stored at 4 degrees
Celsius until genotyping was performed within 24 hours.
HPV genotyping
The Linear Array genotyping system uses polymerase
chain reaction (PCR) amplification of DNA, followed by
a reverse line blot hybridization assay to detect amplified
DNA products (amplicons). The reaction volume consists
of 50μl of Linear Array-HPV master mix and 50 μl of
DNA. The PCR amplification reaction involved an initial
activation step at 95°C for 9 minutes, followed by 40
cycles of denaturation at 95°C for 30 seconds) annealing at
55°C for 1 minute, extension at 72°C for 1 minute, with a
final extension at 72°C for 5 minutes [19]. The reaction
uses PGMY 09/11 primers to detect HPV types. A total of
37 types of HPV are detectable (6, 11, 16, 18, 26, 31, 33,
35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64,
66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84, IS39 and
CP6108) [20]. Type-specific oligonucleotide probes were
used to differentiate hybridised HPV types. A test for the
β-globin gene was used to determine specimen adequacy
and PCR inhibition. Samples without β-globin were re-
tested where possible a second time and rendered invalid if
β-globin DNA was not able to be amplified. Detection of
HPV type 52 was based on a probe which is also known to
signal in the presence of HPV types 33, 35 and 58. There-
fore, samples positive for HPV type 52 only contributed to
the calculated prevalence of HPV 52 if they were negative
for all of the potentially cross-reacting HPV types. Similar
methods have been adopted elsewhere [17].
We classified HPV types according to the International
Agency for Research on Cancer 2009 assessment of
biological agents [21]. HPV types that were classified
as oncogenic were 16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
58, 59 (group 1 carcinogens; sufficient evidence for
cervical cancer) and 68 (a group 2A carcinogen; limited
evidence in humans with strong mechanistic evidence
for cervical cancer).
Data analysis
The representativeness of the study sample in relation to
all women in New Zealand with a high grade cytology
report was assessed by comparing age and ethnicity
distribution with data from the NCSP for all women
with a high grade cytology report [22]. The prevalence
(and 95% confidence intervals) of oncogenic HPV was then
assessed in all women with a high grade cytology report, in
women with confirmed CIN 2 or CIN 3 (CIN 2/3), and for
all women with CIN 2 or worse (CIN2+). A chi-square
test for trend by age was applied to the relative propor-
tion of the prevalence of grouped oncogenic HPV types
(group 1: type 16 and/or18; group 2: other high risk
types not 16 or18 [OHR]; group 3: any oncogenic type)
separately in CIN2, CIN 3, and CIN 2/3 combined. For
this analysis, participants were categorized into one of
three age categories: 20–29, 30–39, and 40–69 years.
Comparison with other countries
The prevalence of oncogenic HPV observed in confirmed
CIN 2+ in New Zealand was compared with the findings
of a prior study conducted in Melbourne [9]. This study
recruited 1,679 clinic attendees at colposcopy clinics, most
of whom (97%) were attending following an abnormal
cytological result. HPV typing was performed using Roche
Linear Array on DNA extracted from PreservCyt-
stored specimens using the MagNA Pure LC system.
The Australian study used an in-house primer to detect
HPV type 52 in the subset of infections where the
standard PGMY09/11 primers were also positive for
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HPV types 33, 35 and 58 [23]. The chi-square test was
used to assess any differences in the reported preva-
lence of oncogenic HPV in confirmed CIN2+ between
the two countries.
In addition, study findings for the type-specific prevalence
of oncogenic HPV in histological CIN 2/3 (excluding AIS)
were compared with results for histologically-confirmed
CIN derived from a worldwide meta-analysis of HPV
prevalence in high grade disease [24]. The original
meta-analysis included both cytologically defined high
grade lesions and histologically confirmed disease; but
for the current comparison a sample-weighted prevalence
of confirmed CIN2/3 was calculated for each reported
HPV type for each region after excluding cytology-defined
disease, using similar methods as those reported for the
original results [24]. The regions for which a weighted
prevalence was re-calculated were Asia, Europe, North
America, and South/Central America. An updated
meta-analysis on the worldwide distribution of HPV
prevalence has also been published [3] but direct com-
parisons with those results could not be made here
because geographic summaries of type-specific prevalence
used combined cytology and histology classifications for
high grade disease.
Analysis software and ethical approvals
Analyses were undertaken using SAS V9.2 statistical
software (Cary, NC, USA). Ethical approval for the study
was obtained from the National New Zealand Ethics
Committee, Cancer Council NSW Human Research
Ethics Committee, Australia, and the University of Sydney
Human Research Ethics Committee, Australia.
Results
Study population
A total of 2170 women were notified to the NCSP-R as
having a high grade cytology report (ASC-H/HSIL+/AGC/
AIS) over the recruitment period (Figure 1). Of these, 948
were able to be contacted and were identified as eligible to
participate in the study (most non-participants could not
be contacted in time to obtain an HPV test sample at
colposcopy, or to request permission to use the residual
cytology material). Of these, a total of 594 (63%) consented
to participate and provided a sample for HPV testing with a
valid HPV test result. Overall, 27% of the original popula-
tion identified as potentially eligible were included in the
final analysis, after taking into account exclusions, ability to
contact women, consent and HPV test success rates.
Among the women with high grade cytology and a valid
Figure 1 Participation in the study.
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HPV test, 529 (89%) also had a valid histology result. Of
these, 61% were diagnosed with a histologically-confirmed
CIN 2, CIN3, AIS or glandular dysplasia, 2.2% were
diagnosed with invasive cervical cancer (including a
small proportion with metastatic disease) and 25.9%
had confirmed low grade lesions or a negative finding
on colposcopy and/or histology (Table 1).
Of the women for whom an HPV test result was
available, approximately 45% were aged between 20–29
years, and the remainder were aged between 30–69 years.
A total of 16.5% identified themselves as Māori, 2.4% as
Pacific peoples, 2.7% as Asian, and 78.5% as European or
“other” (Table 2). Overall, the study sample had a similar
age and ethnicity distribution to the broader population of
women in New Zealand with a high grade cytology report
(Table 2) [15]. Only 7 women (~1%) reported that they
had received the HPV vaccine.
Prevalence of oncogenic HPV
Oncogenic HPV was detected in 86.7% (n=515) of 594
women with a high grade cytology report and a valid
HPV test (Table 3). This proportion increased to 94.9%
when the study population was restricted to women with
a histologically-confirmed diagnosis of CIN2+ (n= 375).
Among women with a high grade cytology report and a
valid HPV test, the most common HPV types detected
were HPV 16 (44.1%), followed by HPV 52 (16.8%) and
HPV 31 (15.2%). In the sub-group with confirmed
disease (CIN 2+) the prevalence of these types were
51.2%, 18.9% and 17.1%, respectively (Table 3).
The combined prevalence of oncogenic HPV types
16 and 18 was 52.9% among women with a high grade
cytology report, 52.6% in women with histologically-
confirmed CIN 2, and 66.4% in confirmed CIN3; whereas
for other oncogenic types it was 33.8%, 42.8% and 28.3%,
respectively (Table 3). A significant inverse age-specific
trend was observed in the relative prevalence of types 16/
18 versus other HR types in women with histologically-
confirmed CIN 2/3 and in CIN 3 (Figure 2). The highest
relative prevalence of HPV 16/18 was observed among
women aged 20–29 years (CIN 2/3: trend p=0.0006; CIN 3:
trend p=0.002), whereas the highest relative prevalence of
OHR types was observed in women aged 40–69 years
Table 1 Final histological diagnosis for study participants
Histology result N %
Histologically-confirmed CIN 2+ 375 63
Cancer 13 2.2
Cervical cancer - primary* 11 1.9
Cervical cancer - (metastatic disease) 2 0.3
High grade lesion (CIN 2/3 – including AIS) 362 60.9
CIN 3 204 34.3
CIN 2 152 25.6
AIS or glandular dysplasia 6 1.0
<CIN 2+ 219 37
Low grade lesion 88 14.8
CIN 1 63 10.6
Other low grade abnormality** 25 4.2
Negative 66 11.1
Other non-significant abnormality† 38 6.4
Negative/normal 28 4.7
No biopsy taken/reported 61 10.3
Insufficient for diagnosis 4 0.7
Total sample size 594 100%
CIN cervical intra-epithelial neoplasia; AIS adenocarcinoma in situ.
* Invasive adenocarcinoma, invasive squamous cell carcinoma, microinvasive
squamous cell carcinoma, other primary epithelial malignancy and
adenosquamous carcinoma.
** Histological appearance infection with human papillomavirus (HPV),
Condyloma acuminatum, Dysplasia/CIN not otherwise specified (NOS).
†Inflammation, squamousmetaplasia, polyp, other.
Table 2 High grade cervical smear cytology report by age
and ethnicity among study participants and among women
on the National Cervical Screening Programme-Register





n % N (Jan-Jun 2009) %
Age groups
20-24 148 24.9 514 22.9
25-29 136 22.9 479 21.4
30-34 92 15.5 348 15.5
35-39 79 13.3 279 12.4
40-44 52 8.8 179 8.0
45-49 34 5.7 165 7.4
50-54 25 4.2 102 4.6
55-59 17 2.9 69 3.1
60-64 7 1.2 73 3.3
65-69 4 0.7 34 1.5
Ethnicity groups
European/Other 466 78.5 1678 74.9
Maori 98 16.5 367 16.4
Asian 16 2.7 127 5.7
Pacific 14 2.4 70 3.1
Total 594 100 2242 100
* The New Zealand NSCP-R contains cervical cytology results for all women in
New Zealand, with the exception of those who choose to opt-off . For the study,
and on the NCSP-R, a high grade cytology report includes women with a
reported cytology result of either high grade squamous intra-epithelial lesion
(HSIL), atypical squamous cells, cannot rule out a high grade lesion (ASC-H),
atypical glandular cells(AGC), adenocarcinoma in situ (AIS) or cytology suggestive
of invasive cancer (SC, AC1-AC5).R
Screened women with high grade cytology as reported in New Zealand for the
period 1st January-30th June 2009 [15].
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(CIN 2/3 trend p=0.007; CIN 3 trend p=0.01). No similar
trends were observed in CIN 2. Further details on the
age and type-specific prevalence of HPV are provided in
Additional file 1: Appendix Tables 1A and 2A.
HPV prevalence in high grade lesions in New Zealand
compared with Australia
The prevalence of any oncogenic HPV type in women
with histologically-confirmed CIN 2+ was significantly
higher in New Zealand compared with that reported in
Australia (94.9% vs. 91.0%; p=0.04) (Table 4). HPV 16 was
the most common type in both countries (51.2% in New
Zealand and 51.4% in Australia). HPV 18 infection rates
were not statistically significantly different between the
countries (12.1% in New Zealand vs. 9.2% in Australia),
although combined rates of infection for HPV16 and/or
18 appeared slightly higher in New Zealand (60.6% in
New Zealand vs. 57.2% in Australia). Significantly higher
reported prevalence of HPV types 52, 58 and 68 were
observed in New Zealand compared with Australia
(Table 4). The prevalence of type 52 was reported as 13.9%
in Australia compared to 18.8% in New Zealand.
HPV prevalence in high grade lesions in New Zealand
compared with countries in other regions
Compared with other regions included in the worldwide
meta-analysis [24], the prevalence of any oncogenic HPV
type in women with histologically-confirmed CIN 2/3
(excluding women with cancer, AIS or glandular lesions)
was greater in this ‘enriched’ New Zealand population
(94.9%) compared with either Asia (78%), Europe (87.3%),
North America (78.8%) or South/Central America (77.9%)
(Table 4).
The prevalence of HPV 16 in CIN 2/3 in this enriched
population of women was 50.8% (Table 4). This was
similar to that observed in Europe (51.5%), but higher
than Asia (33.7%), North America (33.5%) and South/
Central America (37.6%). Similarly, HPV 18 appeared
marginally higher in New Zealand (12.1%) compared
with North America (8.3%), and was approximately
twice as high as observed in Asia (6.0%), Europe (6.5%)
and South/Central America (5.4%). The reported preva-
lence of HPV 52 was much higher than that reported
compared with non-Oceania regions, and almost double
that reported for Asia (18.8% vs. 9.5%).
Table 3 Type specific prevalence of oncogenic HPV infection in women with (1) ASC-H/HSIL cytology*, (2)
histologically-confirmed grade CIN 2 and (3) ≥ CIN 3
ASC-H/HSIL cytology*† (N=594) CIN 2† (N=152) ≥ CIN 3†‡ (N=223)
HR HPV type n % 95% CI n % 95% CI n % 95% CI
16 262 44.1 (40.1 - 48.2) 70 46.1 (37.9 - 54.3) 122 54.7 (47.9 - 61.4)
52 β 100 16.8 (13.9 - 20.1) 24 15.8 (10.4 - 22.6) 47 21.1 (15.9 - 27.0)
31 90 15.2 (12.4 - 18.3) 37 24.3 (17.8 - 32.0) 27 12.1 (8.1 - 17.1)
33 70 11.8 (9.3 - 14.7) 26 17.1 (11.5 - 24.0) 21 9.4 (5.9 - 14.0)
18 67 11.3 (8.8 - 14.1) 16 10.5 (6.1 - 16.5) 32 14.3 (10.0 - 19.6)
58 60 10.1 (7.8 - 12.8) 21 13.8 (8.8 - 20.3) 21 9.4 (5.9 - 14.0)
51 54 9.1 (6.9 - 11.7) 12 7.9 (4.1 - 13.4) 24 10.8 (7.0 - 15.6)
39 39 6.6 (4.7 - 8.9) 14 9.2 (5.1 - 15.0) 12 5.4 (2.8 - 9.2)
45 29 4.9 (3.3 - 6.9) 4 2.6 (0.7 - 6.6) 13 5.8 (3.1 - 9.8)
59 26 4.4 (2.9 - 6.3) 5 3.3 (1.1 - 7.5) 12 5.4 (2.8 - 9.2)
35 25 4.2 (2.7 - 6.2) 12 7.9 (4.1 - 13.4) 5 2.2 (0.7 - 5.2)
56 20 3.4 (2.1 - 5.2) 3 2.0 (0.4 - 5.7) 7 3.1 (1.3 - 6.4)
68 14 2.4 (1.3 - 3.9) 4 2.6 (0.7 - 6.6) 4 1.8 (0.5 - 4.5)
16 and/or 18 314 52.9 (48.8 - 56.9) 80 52.6 (44.4 - 60.8) 148 66.4 (59.8 - 72.5)
16 and/or 18 (alone) 112 18.9 (15.8 - 22.2) 33 21.7 (15.4 - 29.1) 49 22.0 (16.7 - 30.0)
OHR 201 33.8 (30.0 - 37.8) 65 42.8 (34.8 - 51.0) 63 28.3 (22.3 - 34.6)
Single HR HPV 277 46.7 (42.6 - 50.7) 70 46.1 (37.9 - 54.3) 117 52.5 (45.7 - 59.2)
Any HR HPV 515 86.7 (83.7 - 89.3) 145 95.4 (90.7 - 98.1) 211 94.6 (90.1 - 97.2)
* High grade cytology includes high grade squamous intra-epithelial lesions (HSIL), atypical squamous cells, cannot rule out a high grade lesion (ASC-H), atypical
glandular cells (AGC), adenocarcinoma in situ (AIS) or invasive cancer.
† Restricted to women with a valid HPV (human papillomavirus) test result.
‡ Includes histologically confirmed CIN 3, AIS, glandular dysplasia or cervical cancer.
β Test positive for infection with HPV type 52 alone; not validated with linear array testing (see text).
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Discussion
This study is the first to estimate the prevalence of
oncogenic HPV among women with high grade lesions
in New Zealand. The findings of this survey confirm
that, as for other regions, HPV 16 is the most common
HPV type among women with a high grade cytology
report and in women with histologically-confirmed
CIN2+. The prevalence of HPV16 in CIN 2/3 in New
Zealand was broadly consistent with that in Australia and
Europe (about 50%) [9] but was higher than that reported
for North America, Asia, and South/Central America
(all less than 40%) [24]. In New Zealand, HPV 18 was
observed in 12.1% of women with a histological diagnosis
of CIN2/3. This was broadly consistent with reported rates
in Australia and North America but more than that
reported in Asia, Europe and South/Central America.
The study has also provided new more detailed informa-
tion than has been reported to date on the pattern of the
Figure 2 Age-specific prevalence of grouped oncogenic HPV types by histology grade (baseline estimate and 95% confidence intervals)*.
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relative prevalence of HPV 16 and 18 infections in high
grade lesions by age. For HPV type 16/18, prevalence
peaked among women aged 20–29 years and fell with
increasing age. Conversely, for the OHR HPV types, preva-
lence was lowest among women aged 20–29 years, and
increased with increasing age to a peak among women aged
40–69 years. This observation is broadly consistent with
patterns observed in the Guanacaste, Costa Rica cohort,
which highlighted a similar pattern for HPV 16 and OHR
types [25]. It is also consistent with the findings of a study
of age-specific HPV prevalence in CIN 3/AIS as registered
in 3 US cancer registries (Michigan, Iowa, California)
between 1994–200 [26], with a study of the age-specific
HPV prevalence in Danish women subsequently diag-
nosed with CIN2/3, [27] and with a study in United
Kingdom which examined the prevalence of HPV 16/18
in histologically-confirmed CIN3 [17]. This age-related
pattern of infection supports a proposed model of disease
development that contends that HPV16 is more likely to
progress to CIN3 precancerous disease within a shorter
period, whereas OHR types progress slowly and less
frequently to precancerous abnormalities [2].
An important strength of the study is that we recruited
from the population-based National Cervical Screening
Program register. A total of 27% of the population initially
identified as potentially eligible were included in the final
analysis, after taking into account exclusions, the ability to
contact women, consent and HPV test success rates. How-
ever, of the women who could be approached a relatively
high consent rate was obtained, and the observed distribu-
tions of age and ethnicity in the study population were very
similar to that in the broader screening population of
women aged 20–69 years with a reported high grade
cytology result in New Zealand (Table 2). The extent of
underlying high grade CIN2+ in the study population of
women with high grade cytology (about 70% overall) was
also very similar to that reported in the population overall
for the first half of 2009 (70.2%) [15]. A similar distribution
of oncogenic HPV types in women with histologically-
confirmed CIN 2+ was observed in women recruited via
both recruitment channels (Additional file 1: Appendix
Table 3A). These findings suggest that the overall study
results are broadly representative of the wider population
of women with high grade cytology.
In our study, and in the prior Australian study, the overall
prevalence of oncogenic HPV in CIN 2/3 appeared to be
somewhat higher than reported other regions. One explan-
ation for this finding is improvements in PCR technology
used to detect and genotype HPV infection. In the period
between studies reported in the worldwide meta-analysis
and the current New Zealand study, PCR testing has
undergone two significant improvements in technology:







Sample weighted mean (%)
n % (95% CI) n % (95% CI) Asia Europe North America South/Central America
16 181 50.8 (45.5-56.2) 274 51.4 (47.1-5.7) 33.7 51.5 33.5 37.6
52β 67 18.8 (14.9-23.3) 74§ 13.9 (11.1-7.1) 9.5 2.0 4.8 4.7
31 62 17.1 (13.4-21.5) 77 14.4 (11.617.7) 5.4 9.5 13.1 6.0
33 47 13.2 (9.9-17.2) 49 9.2 (6.9-12.0) 5.9 8.1 5.0 5.1
18 43 12.1 (8.9-15.9) 49 9.2 (6.9-12.0) 6.6 6.0 8.3 5.4
58β 40 11.5 (8.4-15.3) 37 6.9 (4.9-9.4) 12.2 3.5 6.8 11.2
51 36 10.1 (7.2-13.7) 61 11.4 (8.9-14.5) 5.1 2.0 3.4 4.0
39 27 7.3 (4.8-10.5) 44 8.3 (6.4-11.3) 1.2 1.4 3.7 2.4
35 18 4.8 (2.8-7.5) 24 4.5 (2.9-6.6) 3.3 2.2 2.8 3.9
45 16 4.5 (2.6-7.2) 23 4.3 (3.1-6.8) 0 1.5 2.3 6.0
59 15 4.2 (2.4-6.9) 26 4.9 (3.2-7.1) 2.3 0 1.9 1.0
56 10 2.8 (1.4-5.1) 28 5.3 (3.5-7.5) 3.6 2.9 8.7 2.1
68β 8 2.2 (1.0-4.4) 12 2.3 (1.2-3.9) 1.1 0.2 2.4 0.5
Any β 342 94.9 (92.1-97) 485 91.0 (88.2-3.3) 78.0 87.3 78.8 77.9
Oncogenic HPV includes infection with either type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, or 68; CIN cervical intra-epithelial neoplasia; CIS carcinoma in situ.
* Limited to women with histologically-confirmed CIN 2/3. Excludes AIS, glandular dysplasia or cervical cancer. As discussed in the text, the population was ‘enriched’
because all were originally referred with high grade cytology.
† From Stevens et al. (2009). [9].This study included histologically-confirmed CIN 2+, but squamous cell carcinoma constituted only 9 of 533 cases.
‡ Re-calculated from data in [24] (see text). African region had no studies with HPV type-specific measurement in histologically-confirmed high grade disease.
β Statistically significant difference in prevalence between New Zealand and Australia when compared using HPV prevalence in CIN 2 from both studies.
§ HPV type 52 detected via Linear Array in the absence of types 33, 35 or 58; or confirmed via an in-house probe designed to detect type 52 within this subgroup
of co-infections. Results for type 52 alone not validated for linear array testing.
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the development of new oligonucleotide primers
(PGMY09/11) and the inclusion of an AmpliTaqGold
polymerase. PGMY09/11 primers were designed using
DNA sequence homology for various HPV types indi-
cated within the highly conserved region of the L1
region. In contrast to this method of designing primers,
the original ‘manos’ MY09/11 primers used in previous
prevalence studies were ‘degenerate’, which meant they did
not necessarily provide reproducible estimates of HPV
types detectable in samples [20]. The improvement in
design accompanying the PGMY primers translated into
greater sensitivity for detecting HPV types 26, 35, 42, 45,
52, 54, 55, 59, 66, and 73 when compared with the
traditional ‘manos’ MY09/11 primers [20]. In addition
to improvements in primer design, AmpliTaqGold
polyermase, introduced in early 2000, improved enzymatic
characteristics and subsequent sensitivity for detecting
HPV type infections compared with the older AmpliTaq
polymerase [28]. Another factor that may account for the
higher overall prevalence of oncogenic HPV in our study,
relative to previous reports, is the method of recruitment.
In this study, women were recruited following a high
grade cytology report. We then assessed the prevalence of
overall and type-specific oncogenic HPV in the subgroup
of women with histologically-confirmed high grade
disease. Our approach may have led to a more concen-
trated recruitment of women with ‘true’ high grade CIN.
By contrast, previous studies may have been more likely to
have included women with misclassified CIN 2 lesions
[29]. Our clinical approach to enriching the study
population provides a potential addition or alternative
to implementing a recently proposed ‘gold standard’ for
diagnosing CIN2/3 histology, involving use of laser
capture microdissection to characterize the molecular
features of suspected pre-cancerous lesions.
In the current study it was assumed that samples posi-
tive for type 52 alone represented true type 52 infection,
but that samples testing positive for 52 and also for at
least one of types 33, 35 and 58 were not truly positive
for type 52 (i.e. it was assumed apparent type 52 reactivity
represented cross-reactivity). Dedicated probes are required
for accurate detection of HPV type 52 in the presence
of multiple infections [9]. However, in practice, cross-
reactivity was not a major concern in the current study
since only one sample was positive for another type in
addition to type 52. Because of our conservative ap-
proach to this aspect of the analysis, our finding of a
high prevalence for type 52 may be, if anything, a slight
underestimate.
This study provides a baseline measure of oncogenic
HPV prevalence in a population of women in New Zealand,
and provides a baseline for future similar surveys to assess
the impact of HPV vaccination. Genotyping studies for high
grade lesions have previously been included in a list of key
recommendations to monitor the effect of HPV vaccination
[30]. Our findings imply that the current HPV vaccination
program in New Zealand, which involves delivery of a
vaccine against HPV types 16/18, could prevent up to 62%
of high grade lesions (53% of CIN 2 and 66% of CIN 3+).
These estimates are based on the assumption (in the best
case for vaccination) that co-infection of other oncogenic
types, in the presence of HPV 16 and/or 18, was not caus-
ally responsible for the development of the majority of high
grade lesions in the current study; if this assumption does
not hold then the proportion of vaccine-preventable high
grade lesions could be considerably lower. These estimates
of potential vaccine effect should be considered highly
provisional, and a number of other factors will be influen-
tial, including vaccine program coverage in New Zealand,
prior expose of the catch-up cohort to vaccine-included
HPV types, and the potential for cross-protection against
non-vaccine-included types. Further surveillance of onco-
genic HPV infection in histologically-confirmed high grade
disease in the post-vaccination era in New Zealand will
continue to be informative.
Conclusions
The baseline assessment of oncogenic HPV prevalence
in New Zealand women with high grade disease provides
insight into the potential burden of disease avertable
with HPV vaccination. The combined prevalence of
oncogenic HPV 16 and 18 in New Zealand was found to
be approximately 62% in confirmed high grade lesions.
Ongoing surveillance of the prevalence of oncogenic
HPV in high grade disease will allow future assessment
of the impact of the national HPV immunization program
in New Zealand.
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Additional file 1: Appendix Figure 1A. Recruitment process for
women who provided a sample during colposcopy. Figure 2A.
Recruitment process for women approached to provide consent to test
after a high grade cytology result used to notify NCSP-R. Table 1A.
Oncogenic HPV prevalence by age in high grade cytology and in
histologically-confirmed CIN 2/3. Table 2A. Oncogenic HPV prevalence
by age in histologically-confirmed disease, by subcategory (CIN2, CIN3
and CIN2/3 combined). Table 3A. Type-specific prevalence of oncogenic
HPV in histologically-confirmed CIN2+ by sample collection method†.
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